Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition
- 25 August 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (9) , 724-734
Abstract
Drug resistance is a leading cause for the failure of cancer treatments. Plasticity of cancer cells to acquire stem cell-like properties enables them to escape drug toxicity through different adaptive mechanisms. Eliminating cancer stem cells (CSCs) can potentially improve treatment outcomes for patients. To determine the role of CSCs in resistance of colorectal cancer cells to targeted therapies and identify treatment strategies, we treated spheroids of BRAFmut and KRASmut colorectal cancer cells with inhibitors of the mitogen-activated protein kinase pathway and studied resistance mechanisms through gene and protein expression analyses. We found that treatments activated several oncogenic pathways and expression of CSC markers CD166 and ALDH1A3. We identified a specific combination treatment using trametinib and mithramycin A to simultaneously inhibit the CSC phenotype and activities of several pathways in cancer cells. This study demonstrates the feasibility of therapeutic targeting of CSCs as a strategy to block tumorigenic activities of cancer cells.Keywords
Funding Information
- National Cancer Institute (CA216413)
This publication has 68 references indexed in Scilit:
- Epigenetic and genetic features of 24 colon cancer cell linesOncogenesis, 2013
- Salinomycin as a Drug for Targeting Human Cancer Stem CellsJournal of Biomedicine and Biotechnology, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB ReceptorsCancer Research, 2012
- Partners in crime: the TGFβ and MAPK pathways in cancer progressionCell & Bioscience, 2011
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaCancer, 2011
- Clonogenic Assay: Adherent CellsJournal of Visualized Experiments, 2011
- Characterization of the Intestinal Cancer Stem Cell Marker CD166 in the Human and Mouse Gastrointestinal TractGastroenterology, 2010
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput ScreeningCell, 2009
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005